For more information, contact the
NLCP staff by email at
NLCP@rti.org or phone at (919) 541-7242.
ODAPC issues guidance regarding Coast Guard drug and alcohol testing On July 13, 2017, DOT’s Office of Drug and Alcohol Policy and Compliance (ODAPC), along with the Office of General Counsel (2OGC), issued guidance on 49 CFR Part 40 in the form of a Q&A. Like all ODAPC/OGC Q&As, this Q&A constitutes official and authoritative guidance and interpretation. Te Q&A explains whether the United
States Coast Guard (USCG) is a DOT Agency with respect to the DOT’s drug and alcohol testing regulation, 49 CFR Part 40. Specifically, the guidance quotes the USCG’s regulation at 46 CFR §16.113(a) as stating, “drug testing programs required by this part must be conducted in accordance with 49 CFR part 40, Procedures for Transportation Workplace Testing Programs.” However, with respect to alcohol testing, the guidance quotes USCG’s regulation at 46 CFR §16.500(a) (2) as stating, “the provisions in 49 CFR part 40 for alcohol testing do not apply to the Coast Guard or to marine employers, and alcohol testing data is not required or permited to be submited by this section.” As a result, ODAPC concludes that because the USCG regulation, 46 CFR Part 16, incorporates Part 40 for drug testing, the USCG is a DOT agency for the drug testing component of Part 40. But because Part 40 does not apply to alcohol testing under 46 CFR Part 16, the USCG is not a DOT agency with respect to the alcohol testing component of 49 CFR Part 40, including subparts J–N. View the guidance in its entirety at
htps://
www.transportation.gov/sites/ dot.gov/files/pictures/07_17_Part40_ QA_A.pdf.
www.datia.org
SAMHSA publishes list of blind specimen suppliers SAMHSA’s Division of Workplace Programs (DWP) compiled a list of blind sample suppliers, for information purposes only, to facilitate compliance with the Mandatory Guidelines for Federal Workplace Drug Testing Programs. Te list does not constitute an endorsement for any or all of the suppliers. It reflects solely the information supplied to DWP by those suppliers who requested inclusion on the list. Te list is on the SAMHSA website: htps://
www.samhsa.gov/sites/ default/files/workplace/blind-sample- suppliers-082012.pdf. Any supplier interested in having its
name added to the list should contact Giselle Hersh at 240-276-2600 or by email
atGiselle.hersh@samhsa.hhs.gov.
DEA proposes to reduce manufactured controlled substances in 2018 Te U.S. Drug Enforcement Administration (DEA) is proposing a reduction for controlled substances that may be manufactured in the U.S. next year by 20 percent as compared to 2017, per the
proposed notice published in the Federal Register on August 7, 2017. Te DEA has proposed to reduce more commonly prescribed schedule II opioid painkillers, including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine, and fentanyl. Demand for these opioid medicines has dropped, according to sales data obtained by DEA from IMS Health, a company that provides insurance companies with data on prescriptions writen and prescription medications sold in America. Te Proposed Aggregate Production Quotas (APQ) for Schedule I and II controlled substances that is published in the Federal Register reflects the total amount of controlled substances needed to meet the country’s legitimate medical, scientific, research, industrial, and export needs for the year and for the maintenance of reserve stocks. Te DEA must balance the production of what is needed for legitimate use against the production of an excessive amount of these potentially harmful substances. For more information, view the proposed notice at htps://
www.gpo.gov/fdsys/pkg/ FR-2017-08-07/pdf/2017-16439.pdf. ❚
datia focus 39
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
